Skip to main content

Research Repository

Advanced Search

All Outputs (50)

A novel zinc finger gene, ZNF465, is inappropriately expressed in acute myeloid leukaemia cells (2015)
Journal Article
Collin, J. F., Wells, J. W., Czepulkowski, B., Lyne, L., Duriez, P. J., Banham, A. H., Mufti, G. J., & Guinn, B. A. (2015). A novel zinc finger gene, ZNF465, is inappropriately expressed in acute myeloid leukaemia cells. Genes, Chromosomes and Cancer, 54(5), 288-302. https://doi.org/10.1002/gcc.22242

To increase our knowledge of leukaemia‐associated antigens, especially in acute myeloid leukaemia (AML) M4, we prepared a phage display cDNA library using mRNA from the bone marrow cells of a patient with AML M4 at diagnosis. We immunoscreened 106 pf... Read More about A novel zinc finger gene, ZNF465, is inappropriately expressed in acute myeloid leukaemia cells.

Infrequent expression of the Cancer-Testis antigen, PASD1, in ovarian cancer (2015)
Journal Article
Khan, G., Brooks, S. E., Mills, K. I., & Guinn, B.-A. (2015). Infrequent expression of the Cancer-Testis antigen, PASD1, in ovarian cancer. Biomarkers in Cancer, 7, 31–38. https://doi.org/10.4137/bic.s28378

Ovarian cancer is very treatable in the early stages of disease; however, it is usually detected in the later stages, at which time, treatment is no longer as effective. If discovered early (Stage I), there is a 90% chance of five-year survival. Ther... Read More about Infrequent expression of the Cancer-Testis antigen, PASD1, in ovarian cancer.

Oral tolerance to cancer can be abrogated by T regulatory cell inhibition (2014)
Journal Article
Whelan, M. C., Casey, G., Larkin, J. O., Guinn, B. A., O'Sullivan, G. C., & Tangney, M. (2014). Oral tolerance to cancer can be abrogated by T regulatory cell inhibition. PLoS ONE, 9(5), Article e97602. https://doi.org/10.1371/journal.pone.0097602

Oral administration of tumour cells induces an immune hypo-responsiveness known as oral tolerance. We have previously shown that oral tolerance to a cancer is tumour antigen specific, non-cross-reactive and confers a tumour growth advantage. We inves... Read More about Oral tolerance to cancer can be abrogated by T regulatory cell inhibition.

PASD1: A Promising Target for the Immunotherapy of Haematological Malignancies (2013)
Journal Article
Khan, G., Denniss, F., Mills, K. I., Guinn, B.-A., & Pulford, K. (2013). PASD1: A Promising Target for the Immunotherapy of Haematological Malignancies. Genetic Syndromes and Gene Therapy, 04(09), Article 186. https://doi.org/10.4172/2157-7412.1000186

In general, there is a lack of good immunotherapy targets within the spectrum of haematological malignancies. However haematopoietic stem cell transplants and continuing antigen discovery have allowed further insight into how further improvements in... Read More about PASD1: A Promising Target for the Immunotherapy of Haematological Malignancies.

An analogue peptide from the cancer/testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide (2013)
Journal Article
Hardwick, N., Buchan, S., Ingram, W., Khan, G., Vittes, G., Rice, J., Pulford, K., Mufti, G., Stevenson, F., & Guinn, B. A. (2013). An analogue peptide from the cancer/testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide. Cancer Immunology Research, 13(3), 16-26. https://doi.org/10.1158/1424-9634.DCL-16.13.3

We have previously identified the novel Cancer/Testis antigen PASD1 by immunoscreening a testis library with pooled acute myeloid leukemia (AML) patient sera. To develop a cytotoxic T lymphocyte (CTL)-inducing vaccine, we have now investigated the ca... Read More about An analogue peptide from the cancer/testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation (2013)
Journal Article
Liberante, F. G., Pellagatti, A., Boncheva, V., Bowen, D. T., Mills, K. I., Boultwood, J., & Guinn, B. A. (2013). High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation. British journal of haematology, 162(2), 282-285. https://doi.org/10.1111/bjh.12352

New targets for the immunotherapy of colon cancer - Does reactive disease hold the answer (2013)
Journal Article
Boncheva, V., Bonney, S. A., Brooks, S. E., Tangney, M., O'Sullivan, G., Mirnezami, A., & Guinn, B. A. (2013). New targets for the immunotherapy of colon cancer - Does reactive disease hold the answer. Cancer Gene Therapy, 20(3), 157-168. https://doi.org/10.1038/cgt.2013.5

Colorectal cancer (CRC) is one of the most commonly diagnosed cancers in both men and women, posing a serious demographic and economic burden worldwide. In the United Kingdom, CRC affects 1 in every 20 people and it is often detected once well establ... Read More about New targets for the immunotherapy of colon cancer - Does reactive disease hold the answer.

Innovative evolution of cancer gene and cellular therapies (2013)
Journal Article
Lam, P., Khan, G., Stripecke, R., Hui, K. M., Kasahara, N., Peng, K. W., & Guinn, B. A. (2013). Innovative evolution of cancer gene and cellular therapies. Cancer Gene Therapy, 20(3), 141-149. https://doi.org/10.1038/cgt.2012.93

We provide an overview of the latest developments in cancer gene therapy - from the bench to early-stage clinical trials. We describe the most recent work of worldwide teams including experienced scientists and clinicians, reflecting the recent emerg... Read More about Innovative evolution of cancer gene and cellular therapies.

Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia (2011)
Journal Article
Smits, E. L., Lee, C., Hardwick, N., Brooks, S., Van Tendeloo, V. F., Orchard, K., & Guinn, B. A. (2011). Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia. Cancer Immunology, Immunotherapy, 60(6), 757-769. https://doi.org/10.1007/s00262-011-1022-6

Immunotherapy is currently under active investigation as an adjuvant therapy to improve the overall survival of patients with acute myeloid leukaemia (AML) by eliminating residual leukaemic cells following standard therapy. The graft-versus-leukaemia... Read More about Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.